Clinical Trial Update: TheraSphere With Durvalumab and Tremelimumab for HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TheraSphere in combination with durvalumab and tremelimumab for hepatocellular carcinoma is active but not recruiting. The study is s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• TheraSphere (yttrium-90 glass microspheres)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING